On July 14, 2026, the Federal Trade Commission secured a settlement with Caremark Rx LLC and Zinc Health Services LLC that will require the pharmacy benefit manager to adopt meaningful changes to its business practices. The agreement reflects the agency's continued focus on the role of PBMs in prescription drug pricing and represents one of the more consequential federal enforcement actions in this sector to date. For PBMs, health plans, pharmacies, and their counsel, the settlement is a strong indicator that the compliance environment surrounding pharmacy benefit management is entering a new phase.
The mandated reforms concentrate on three interrelated priorities. First, the settlement directs changes intended to reduce patients' out-of-pocket costs at the pharmacy counter, an area that has drawn sustained attention from federal regulators and state legislatures alike. Second, it imposes heightened obligations related to pricing and rebate transparency, targeting the flow of information between PBMs, plan sponsors, manufacturers, and consumers. Third, it addresses the treatment of community pharmacies, seeking to ensure that network participation, reimbursement, and contracting practices are administered fairly. Together, these commitments touch nearly every operational dimension of a modern PBM business.
The broader significance of the settlement lies in the direction it signals. Heightened FTC scrutiny of PBM practices may prompt additional enforcement actions, invite closer coordination with state attorneys general, and encourage private litigation testing the boundaries of transparency and fair-dealing obligations. Industry participants should anticipate that regulators, plan sponsors, and pharmacy partners will increasingly expect documented compliance with the themes reflected in this action, even where they are not directly bound by its terms.
In light of these developments, PBMs, health plans, and pharmacies would be well advised to reassess existing contractual arrangements, rebate and pricing disclosure practices, formulary design processes, and pharmacy network policies. Careful attention to internal controls, data governance, and communications with plan sponsors and members will help mitigate enforcement and litigation risk in the coming months. Documentation of good-faith compliance efforts will likely prove valuable as expectations continue to evolve.
This article is provided for general informational purposes only and does not constitute legal advice. Clients and other readers facing specific questions about the settlement's implications should seek tailored counsel from a qualified attorney.